Member Info for TR64

DrugMePlese
They are not dividend re investments, they are director buys.

If you have 50,000 shares, I wonder why you post at all.

Never rely on investor mags or such, everything is there , publications of latest news like GSK JV's with real biotech companys.

GSK never entered into buying 10% of Curevac on a wing an prayer, they knew what they were investing in

Like wise with VIR, these are strategic investments and JV's, that no other major pharma as been able to do..

CSO Hal Baron January 11 Brought 2558 shares , cost £48,692

DrugMePlease, large insider buys
Manvinder Singh Banga BUY £503,448 shares purchased 36,600

Ortex have GSK target of £16.65

11 Analysts representing investments managers have GSK as BUY
2 as a sell

The dribbles proactive investors and CS come out with is just for shorter's.

Proactive Investors have long been the scourge of promoting BS

Note how LSE.CO.UK allow constant multiple avatars to promote witch hunts, most of these avatars are based in Asia , a time is coming where LSE and ADVFN get fined

Eligo Bioscience has entered into a research and option agreement with GlaxoSmithKline (GSK) aimed at advancing Eligobiotics for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation.

Acne is a chronic inflammatory disorder, affecting 85% of adolescents and young adults around the world and carrying a significant impact on physical and mental health globally.

Eligo’s acne discovery programme, EB005, applies Eligobiotics technology to precisely modify the composition of the skin’s microbiome to treat or reduce the risk of developing moderate to severe acne. Eligo is leveraging recent insights in acne showing that otherwise beneficial skin bacteria, when expressing pro-inflammatory molecules, trigger the immune system and drive inflammation. EB005 aims to develop Eligobiotics for topical application to precisely and selectively remove these pro-inflammatory bacterial strains from the microbiome, while sparing the rest of the skin microbiome.

Under the agreement, Eligo will receive an upfront payment and research and development funding to advance EB005 until preclinical proof of concept. If GSK exercises its option, both companies will enter into a licence and collaboration agreement to jointly continue the development of EB005 in acne. Eligo would be eligible to receive up to a total of $224 million in licence fees and potential milestone payments, as well as royalties on global sales.

Emmanuel Hanon, Senior Vice-President and Head of R&D for GSK Vaccines, commented: “We are delighted to join forces with Eligo, a biotech company that is pioneering microbiome engineering by leveraging CRISPR technology to address microbiome-associated diseases.

“This partnership builds on GSK’s strong expertise in immunology, bacteriology and product development, and Eligo’s robust bacteriophage science, to help improve acne patients’ lives.”

GSK partner VIR lays out the real need for treatment
It’s important for antibodies to 'control the virus as it evolves': Vir Biotechnology CEO

George Scangos, Vir Biotechnology President and CEO joins Yahoo Finance Live to weigh in on the surge of COVID-19 cases across the U.S. and discuss why it’s crucial to rollout COVID-19 vaccines efficiently.

Video Transcript
- Let's not forget the added efforts here coming through in terms of the therapies for people struggling through COVID as well. We've seen antibody ****tails play a significant role in all of that. And one of the companies pairing up with GlaxoSmithKline on that effort has been Vir Biotech. That company has seen about a 30% boost here year to date for their share prices as they continue to work through antibody-tested treatments. For more on that, we're joined here by Vir Biotechnology President and CEO George Scangos joins us here, alongside Yahoo Finance's Anjalee Khemlani.

And George, appreciate you coming on here. You guys mainly have two right now that are working their way through the trial process. Obviously, as I said, a lot of attention on the vaccine side, a lot of excitement there to celebrate. But how important is the progress you guys are making through here and playing your part on treatments for a lot of people as we continue to see cases rise and hospitals deal with that surge?

GEORGE SCANGOS: Yeah, thanks. So first of all, thanks for having me. Happy to be here. Look, the tension recently has certainly been on vaccines, and I think with 95% effective vaccines, that's appropriate. I think we all be grateful that the vaccines work as well as they do. A couple of things to be said, though, that in order for the vaccines to eliminate the infection, we're gonna have to get to herd immunity, which probably means 75% of the people are immune in some way, which probably means vaccinating 80% of the population. I think that will be extremely hard to achieve given the reluctance of a reasonable fraction of the US population to take the vaccine.

The second issue we have to think about is the emergence of all the strains. And I'm sure you've heard about the South African strain, the UK strain

Are you referring to OBX or GSK

Every institution is required by regulation to notify the company shares it disposes of or buys withing 5 working days, the time period is extended by 3 days when a bank holiday occurs

Where is LG , Filing of a TRI ??

GSK is shorted by UK Hedge funds , they work with Capital Group, its already established how occurs.
AZN is next up again

AZN Vaccine as a efficacy figure of 62% in the trail, that figure was based on the 13000 people, the 90% figure came from 2655 people who had mixed dosing

At best 90 people in every 100 will be protected for 6 months, AZN trial was not run over a long period, so it follows that 10 people who have a vaccine will not be protected

GSK Antibody treatment with VIR

https://www.nasdaq.com/market-activity/stocks/vir

Cruise ships rely on port staff at each port of entry, and it will come down to each country weather they will accept any crusie ship docking.

Fred Olsen crusie ship last year was refused permission to dock in Bermuda and then the BVI..
Cuba allowed it to dock and Cuba treated the passenger's on board

As the EX Divi date approaches the c0ckroaches appear

It should be a requirement that to qualify for dividends that you hold for a year.

GSK should be questioning Capital Group on producing TR1 filings

TA.. Its no good referring to Nazi Gold.

CS worked with UK MP Nahdim Zahawwi buying oil from ISIL

Suggest you focus your attention on the Kurd Zahawi and CS, the history goes back to 2003

DECEMBER 7 2020
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) investigational monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs (one of the major sites of infection).

ACTIV-3 is one of several ongoing trials in the NIH’s ACTIV program, an NIH led public-private partnership designed to accelerate development of the most promising treatments and vaccine candidates for COVID-19. ACTIV-3 has been designed as a “master protocol” that allows for the simultaneous evaluation of multiple investigational therapeutics as they become available, but within the same clinical trial structure, across multiple trial sites.

Phase 3 trail in the USA completed already results due,
The UK trail is phase 1, and that came about from VIR-7831 phase 3 in USA Hospitals early December, so it was positive in the USA in Phase 3 before it started in the UK

Are Saga Clientele over 50 years of age, so the most of not all will have had a vaccination, which puts Saga ahead of others
Saga only has 2 cruise ships and its mainly a financial services business

Apologies , slipped on keyboard, it was 8.95 p

Seems like investors have just been funding directors salary's for 11 years with no return at all

Is provexis a Ponzi Scheme that pays executive of the company ? and never returns anything , other than massive dilution, there was a time in 2009, when the SP was 20p

22 January 2021 Subscription Rights and DI Rights cease trading

26 January 2021 Subscription Period and DI Rights Subscription Period ends

29 January 2021 Settlement of New Shares with shareholders and investors; New Shares begin
trading on Main Market for listed securities of the LSE

VIR closed up 11.5%
GSK must be smiling